Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019)
Vericel (VCEL) posted Non-Current Deffered Revenue of $1.9 million for Q2 2019, little changed sequentially from $1.9 million in Q1 2019, and down 3.01% YoY from $2.0 million in Q2 2018.
Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019) Analysis & Trends
Vericel has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $1.9 million in Q2 2019.
- Quarterly Non-Current Deffered Revenue fell 3.01% year-over-year to $1.9 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $1.9 million (down 3.01% YoY) and the FY2018 annual result came in at $1.7 million, down 19.09% from the prior year.
- Non-Current Deffered Revenue steadied at $1.9 million in Q2 2019 per VCEL's latest filing, from $1.9 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.1 million in Q4 2017 and troughed at $900000.0 in Q2 2016.
- A 4-year average of $1.7 million and a median of $1.7 million in 2016 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue soared 74.11% in 2017, then retreated 19.09% in 2018.
- Over 4 years, Non-Current Deffered Revenue stood at $1.7 million in 2016, then climbed by 22.05% to $2.1 million in 2017, then retreated by 19.09% to $1.7 million in 2018, then gained by 14.05% to $1.9 million in 2019.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.9 million, $1.9 million, and $1.7 million for Q2 2019, Q1 2019, and Q4 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 1.90 Mn |
| Mar 31, 2019 | 1.90 Mn |
| Dec 31, 2018 | 1.67 Mn |
| Sep 30, 2018 | 1.81 Mn |
| Jun 30, 2018 | 1.90 Mn |
| Mar 31, 2018 | 1.70 Mn |
| Dec 31, 2017 | 2.06 Mn |
| Sep 30, 2017 | 1.00 Mn |
| Jun 30, 2017 | 900,000.00 |
| Mar 31, 2017 | 1.63 Mn |
| Dec 31, 2016 | 1.69 Mn |
| Sep 30, 2016 | 1.23 Mn |
| Jun 30, 2016 | 820,000.00 |